骨保护素在预测和治疗绝经后骨质疏松症中的应用

被引：15

作者：

丁仁 ^{[1
]}

尹宏 ^{[2
]}

钱卫庆 ^{[2
]}

孙海涛 ^{[1
]}

机构：

[1] 南京中医药大学第一临床医学院

[2] 南京市中医院骨伤科

来源：

国际骨科学杂志 | 2011年 / 32卷 / 01期

关键词：

骨保护素; 绝经后骨质疏松; 骨密度; 标志物;

D O I：

暂无

中图分类号：

R580 [];

学科分类号：

摘要：

骨保护素(OPG)是近年骨科研究的重大进展,它通过OPG/核因子-κB受体活化因子(RANK)/RANK配体(RANKL)系统发挥抗骨质疏松作用,为防治绝经后骨质疏松症开辟了新途径。近年研究均表明,OPG作为骨转换始动因素之一,与骨密度及其他骨转换标志物相比具有更高的敏感性和特异性,因此血清OPG水平有望成为早期预测绝经后骨质疏松症的新一代生化标志物。该文就OPG在预测和治疗绝经后骨质疏松症中的应用作一综述。

引用

收藏

页码：24 / 26

页数：3

相关论文

共 10 条

[1]

北京地区汉族妇女绝经前后护骨素基因多态性与骨密度的关系(英文) [J].

于丽云 ;

周学瀛 ;

邢小平 ;

夏维波 ;

裴育 ;

李梅 ;

矫杰 ;

孟迅吾 ;

徐苓 .

中国临床康复, 2006, (48) :204-207

[2]

Associations between osteoprotegerin polymorphisms and bone mineral density: a meta-analysis [J].

Lee, Young Ho ;

Woo, Jin-Hyun ;

Choi, Seong Jae ;

Ji, Jong Dae ;

Song, Gwan Gyu .

MOLECULAR BIOLOGY REPORTS, 2010, 37 (01) :227-234

[3]

Direct effects of osteoprotegerin on human bone cell metabolism [J].

Grundt, Alexander ;

Grafe, Ingo Alexander ;

Liegibel, Ute ;

Sommer, Ulrike ;

Nawroth, Peter ;

Kasperk, Christian .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 389 (03) :550-555

[4]

Relationships among serum receptor of nuclear factor-κB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory [J].

Nabipour, Iraj ;

Larijani, Bagher ;

Vahdat, Katayoun ;

Assadi, Majid ;

Jafari, Seyed Mojtaba ;

Ahmadi, Esmaeil ;

Movahed, Ali ;

Moradhaseli, Farzad ;

Sanjdideh, Zahra ;

Obeidi, Narges ;

Amiri, Zahra .

MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2009, 16 (05) :950-955

[5]

The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women [J].

Mezquita-Raya, P ;

de la Higuera, M ;

García, DF ;

Alonso, G ;

Ruiz-Requena, ME ;

Luna, JD ;

Escobar-Jiménez, F ;

Muñoz-Torres, M .

OSTEOPOROSIS INTERNATIONAL, 2005, 16 (11) :1368-1374

[6]

Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover [J].

Indridason, OS ;

Franzson, L ;

Sigurdsson, G .

OSTEOPOROSIS INTERNATIONAL, 2005, 16 (04) :417-423

[7]

Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice [J].

Kostenuik, PJ ;

Bolon, B ;

Morony, S ;

Daris, M ;

Geng, ZO ;

Carter, C ;

Sheng, J .

BONE, 2004, 34 (04) :656-664

[8]

Osteoprotegerin-receptor activator of nuclear factor-κB ligand ratio:: A new approach to osteoporosis treatment? [J].

Coetzee, M ;

Kruger, MC .

SOUTHERN MEDICAL JOURNAL, 2004, 97 (05) :506-511

[9]

Osteoprotegerin serum levels in women: Correlation with age, bone mass, bone turnover and fracture status [J].

Fahrleitner-Pammer, A ;

Dobnig, H ;

Piswanger-Soelkner, C ;

Bonelli, C ;

Dimai, HP ;

Leb, G ;

Obermayer-Pietsch, B .

WIENER KLINISCHE WOCHENSCHRIFT, 2003, 115 (09) :291-297

[10]

Osteoprotegerin: A novel secreted protein involved in the regulation of bone density [J].

Simonet, WS ;

Lacey, DL ;

Dunstan, CR ;

Kelley, M ;

Chang, MS ;

Luthy, R ;

Nguyen, HQ ;

Wooden, S ;

Bennett, L ;

Boone, T ;

Shimamoto, G ;

DeRose, M ;

Elliott, R ;

Colombero, A ;

Tan, HL ;

Trail, G ;

Sullivan, J ;

Davy, E ;

Bucay, N ;

RenshawGegg, L ;

Hughes, TM ;

Hill, D ;

Pattison, W ;

Campbell, P ;

Sander, S ;

Van, G ;

Tarpley, J ;

Derby, P ;

Lee, R ;

Boyle, WJ .

CELL, 1997, 89 (02) :309-319